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ABSTRACT
Objectives: The purpose of this study was to identify total lifetime
medical-care costs and costs associated with ﬁrst-line chemotherapy treat-
ment among older patients with stage IIIB/IV non–small-cell lung cancer
treated with commonly used two-drug chemotherapy (“doublet”) regi-
mens in the United States.
Methods: Study patients included individuals aged 65 years and older
who received a diagnosis of stage IIIB/IV non–small-cell lung cancer in a
Surveillance, Epidemiology and End Results cancer registry between 1997
and 2002 and who received ﬁrst-line treatment with commonly used
doublet regimens. Patients were followed retrospectively in the Surveil-
lance, Epidemiology and End Results—Medicare database to evaluate
lifetime medical-care costs and costs while on ﬁrst-line chemotherapy
treatment. Pairwise comparisons of treatment costs were estimated by
using nonparametric bootstrap methods.
Results: Lifetime medical-care costs totaled approximately $70,000 and
on-treatment costs for ﬁrst-line chemotherapy totaled approximately
$30,000 among study patients and were dominated by hospitalization and
physician costs. Lifetime costs were signiﬁcantly higher among patients
treated with ﬁrst-line cisplatin/carboplatin (platinum) plus a taxane com-
pared with those who received platinum plus gemcitabine [difference:
$4781 ($1558–$8039)] or other doublet therapy [difference: $5961
($2333–$9614)]. Total on-treatment costs for ﬁrst-line chemotherapy
were signiﬁcantly higher among patients treated with platinum plus a
taxane compared with those who received platinum plus gemcitabine
[difference: $5825 ($3872–$7770)], platinum plus another agent [differ-
ence: $5968 ($3995–$7975)], or another doublet therapy [difference:
$3663 ($1620–$5740)].
Conclusions: There is a cost differential between ﬁrst-line doublet regi-
mens in terms of lifetime and on-treatment costs. Although doublet
therapy with platinum and a taxane was the most frequently utilized
regimen, it was associated with the highest lifetime and on-treatment
costs.
Keywords: cost analysis, gemcitabine, longitudinal analysis, lung cancer,
pharmacoeconomics.
Introduction
In patients with advanced (stage IIIB/IV) non–small-cell lung
cancer (NSCLC), platinum-based chemotherapy regimens have
provided improvement in short-term survival, symptom control,
and quality of life [1–3]. Doublet therapies or combinations of
newer chemotherapeutic agents, such as taxanes, Vinorelbine,
camptothecin analogs, and gemcitabine along with a platinum,
have been shown in early clinical trials to lead to improved
survival in patients with advanced NSCLC [4,5]. Similar
response rates and survival beneﬁts were demonstrated in recent
clinical trials of platinum-based doublet therapies with the
primary difference seen in the occurrence of adverse events [4,5].
Nevertheless, it is not clear what impact the differences in toxi-
city proﬁles may have on the total medical costs of treating
patients with stage IIIB/IV NSCLC in clinical practice.
Recent emphasis has been placed on the economics of phar-
macologic therapies in oncology. Improved cost-effectiveness
has long been recognized by the American Society for Clinical
Oncology as one of four important clinical outcomes in devel-
oping guidelines for drug use [6]. Nevertheless, there are avail-
able limited data describing costs and medical resource use
associated with ﬁrst-line chemotherapy in individuals with
advanced NSCLC.
Two previous studies have examined costs associated with
NSCLC and found that those who received ﬁrst-line chemo-
therapy had higher lifetime medical-care costs compared with
those who did not and that treatment costs were dominated by
hospitalization costs [7,8]. Nevertheless, these studies did not
examine costs incurred while on ﬁrst-line therapy and used older
data, which did not capture the utilization of paclitaxel and
gemcitabine (approved for advanced or metastatic NSCLC in the
United States in 1998) or docetaxel (approved in 2002) [9]. Thus,
previous database analyses of chemotherapy use have not
adequately captured costs associated with chemotherapies more
recently approved for ﬁrst-line use.
The current study explores more recent data and adds to the
existing medical literature by evaluating both total lifetime and
on-treatment costs incurred by older patients with advanced
NSCLC who received current two-drug chemotherapy
(“doublet”) regimens commonly used in clinical practice. This is
in part accomplished by focusing on the two most frequently
used platinum-based doublets for advanced NSCLC, taxanes
(paclitaxel and docetaxel) and gemcitabine. On treatment, costs
are included in this analysis because they represent a substantial
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fraction of the lifetime costs associated with NSCLC. Addition-
ally, costs associated with the use of supportive medications and
hospitalizations from serious adverse events associated with ﬁrst-
line doublet chemotherapy were estimated. The costs of NSCLC
identiﬁed in these analyses, both at the macro and on-treatment
level, will be of interest to policymakers and value-based
decision-makers.
Methods
Data Source
Linked clinical data from the Surveillance, Epidemiology and
End Results (SEER) Program of the National Cancer Institute
and administrative Medicare claims from the Centers for Medi-
care and Medicaid Services were used to evaluate associated
lifetime and on-treatment costs among older patients with
NSCLC aged 65 years and older, the age group where this cancer
is most prevalent. SEER is an epidemiologic surveillance system
consisting of population-based tumor registries designed to track
cancer incidence and survival in the United States. The registries
routinely collect information on people with cancer who newly
received a diagnosis from multiple reporting sources in geo-
graphically deﬁned areas, which represent approximately 25% of
the US population [10]. Data are ascertained for all recently
diagnosed patients with cancer from multiple reporting sources
such as hospitals, outpatient clinics, laboratories, private medical
practitioners, nursing/convalescent homes/hospices, autopsy
reports, and death certiﬁcates.
SEER data from 1997 to 2002 and Medicare claims
through 2003 were used in the analysis. Combining SEER and
Medicare data provides information on the initial cancer diag-
nosis and later cancer treatment, as well as downstream
medical care for patients with cancer. This combined data
source offers the opportunity to link service utilization over
time to stage at diagnosis, as well as to time from diagnosis to
death. Data evaluated in this study included demographics,
cancer diagnosis information (e.g., site, type, staging), Medicare
enrollment status, and Medicare medical resource utilization
by component (e.g., inpatient hospitalizations, skilled nursing
facility [SNF] hospitalizations, chemotherapy utilization and
administration, outpatient hospital visits, ambulatory services,
physician services, home health-care services, and hospice care)
during follow-up including dates of service, diagnosis, and pro-
cedure codes. Medicare did not provide oral prescription drug
coverage during the study period but provided coverage for
injectable/intravenous drugs not usually self-administered (cap-
turing treatments utilized for NSCLC).
Sample Selection and Follow-Up
Patients aged 65 years and older with a new diagnosis of stage
IIIB/IV lung cancer (SEER cancer site recode 39) between 1997
and 2002 who received ﬁrst-line doublet chemotherapy were
selected for possible inclusion in the study sample. Using Interna-
tional Classiﬁcation of Disease-Oncology-2 (ICD-O-2) histology
codes from the SEER database, the sample was limited to patients
with squamous cell carcinoma, adenocarcinoma, or large cell
carcinoma. Patients were excluded if they were less than 65 years
old at index (i.e., date of NSCLC diagnosis), were enrolled in a
health maintenance organization at any point from 12 months
before index through follow-up, were not eligible for Part A or
Part BMedicare beneﬁts at any point from12months before index
through follow-up, had any other cancer diagnosis before index,
had incomplete data (i.e., inconclusive date of cancer diagnosis),
had Medicare eligibility based on end-stage renal disease or
disability, or had a diagnosis of NSCLC made at time of death or
at autopsy (because it is unclear whether or not the patient would
have known of theNSCLCdiagnosis or received any treatment for
it while still alive).
Study patients were followed retrospectively from their index
date (i.e., date of NSCLC diagnosis) to death or the end of the
Medicare claims data (i.e., December 31, 2003), whichever came
ﬁrst. Because the SEER database contains only the diagnosis
month and year, this analysis follows the common convention of
using the ﬁrst day of the diagnosis month in forming a diagnosis
date to not exclude any relevant resource utilization or costs.
Study Measures
First-line doublet chemotherapy was considered to be the earliest
two-drug chemotherapy regimen received within the initial treat-
ment period. Speciﬁc doublet regimens received were identiﬁed
from Healthcare Common Procedure Coding System codes on
Medicare claims (Appendix SI) and included a platinum (cisplatin
or carboplatin) plus a taxane (docetaxel/paclitaxel) (P + TAX), a
platinum and gemcitabine (P + GEM), a platinum plus another
agent other than a taxane or gemcitabine (P + OTHER), or
another type of doublet therapy excluding a platinum, a taxane, or
gemcitabine (OTHER). The date of treatment was deﬁned as the
date of the ﬁrst chemotherapy claim.Multiple courses of the same
chemotherapy agents were considered part of ﬁrst-line treatment.
Additional chemotherapy agents receivedwithin 8 days of the ﬁrst
drug were considered to be part of the ﬁrst-line chemotherapy
regimen.
Certain clinical outcomes, including treatment discontinua-
tion and length of time on treatment, could not be observed
directly by using variables within the SEER–Medicare data set.
Thus, algorithms for identifying these outcomes were developed
with clinical experts. Discontinuation was deﬁned as the date
when one of the following criteria was observed: 1) receipt of a
new chemotherapy agent that was not part of ﬁrst-line treatment;
2) a gap between successive ﬁrst-line chemotherapy treatments
greater than 60 days; 3) a switch from doublet therapy to a single
chemotherapy regimen lasting more than 30 days; or 4) death
while the patient was still on chemotherapy. Patients were con-
sidered censored if their follow-up ended before treatment dis-
continuation. The length of time on chemotherapy was deﬁned as
the difference in days between the date of discontinuation of
ﬁrst-line therapy and the date of initiation of the ﬁrst-line
regimen.
Lifetime NSCLC-related medical-care costs included inpatient
hospitalization, SNF, outpatient hospital/clinic, home health care,
hospice, and physician service costs. These costs were calculated
for each category of service by summing all Medicare payments,
primary insurer payments, and patient copayments and deduct-
ibles on relevant claims from the index date to death or the end of
follow-up (i.e., December 31, 2003), whichever occurred ﬁrst.
On-treatment NSCLC-related medical-care costs included the
speciﬁc components of care mentioned earlier utilized during
the receipt of ﬁrst-line doublet chemotherapy. The period of
follow-up for analyses of on-treatment costs began at the initia-
tion of ﬁrst-line doublet chemotherapy and continued until 30
days after therapy discontinuation, a switch to another chemo-
therapy regimen, death, or the end of follow-up, whichever
occurred ﬁrst.
Palliative and supportive treatments associated with ﬁrst-line
chemotherapy were identiﬁed by using a relevant ICD-9-CM
procedure orHealthcare Common Procedure Coding System code
(Appendix SI). Costs of hospitalizations due to adverse events
related to the use of ﬁrst-line chemotherapy were identiﬁed from
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hospital claims with an ICD-9-CM diagnosis code indicating a
relevant event.
Data Analysis/Statistical Methods
Summary statistics were used to describe study patients according
to baseline clinical and demographic characteristics including age,
sex, race, presence of comorbidities (reported as Charlson Comor-
bidity Index score calculated in the year before diagnosis), geo-
graphic region, median household income, cancer stage at
diagnosis, and residence in a metropolitan county to identify
characteristics that might inﬂuence study outcomes. Utilization of
speciﬁc ﬁrst-line doublet chemotherapy regimens over the years
1997 through 2003 was also summarized descriptively.
Unadjusted lifetime medical costs and medical costs while
on-treatment with ﬁrst-line chemotherapy were reported over-
all and per month of follow-up by component of care (e.g.,
hospital, SNF, physician, outpatient hospital/clinic, home health,
and hospice care). Descriptive statistics were produced to summa-
rize costs of palliative/supportive treatments and hospitalizations
for adverse events associatedwith ﬁrst-line doublet chemotherapy.
Adjusted total lifetime medical-care costs and total medical
costs while on ﬁrst-line chemotherapy treatment were ﬁrst esti-
mated by using the Kaplan-Meier Sample Average (KMSA)
method [11]. This is a nonparametric approach that adjusts for the
differential follow-up times for patients because follow-up in this
study was truncated at the end of 2003. Second, pairwise com-
parisons between speciﬁc ﬁrst-line doublet chemotherapy regi-
mens in mean lifetime total medical costs and total medical costs
while on ﬁrst-line chemotherapy treatment were analyzed statis-
tically by using the propensity score bin bootstrapping approach
[12]. This approach utilizes nonparametric bootstrapping to esti-
mate mean costs while avoiding distributional assumptions
[13,14] and allows for adjustment for potential selection bias
through the use of the propensity score stratiﬁcation [15]. The ﬁrst
step in the propensity score bin bootstrapping approach was
estimating propensity scores for each pairwise comparison using a
logistic model with the following covariates: sex, race, age, urban/
rural, geographic region, stage at diagnosis, and Charlson comor-
bidity index score. Estimates of propensity scores were then
grouped into ﬁve strata based on quintiles (lowest 20% of scores
in strata 1 to highest 20% of scores in strata 5), and overlap in the
Starting NSCLC
Sample Size 
(N = 81,640)
Exclusion Criteria: Remaining Sample
1. Aged ≤ 65 at diagnosis N = 69,821
2. History of other cancer prior to NSCLC diagnosis N = 59,310
3. Stage 0 or unknown at diagnosis N = 55,322
4. Gap in Part A or B Medicare coverage in 12 months prior to index through follow-up N = 49,817
5. Medicare HMO enrollment in 12 months prior to or during study period N = 35,084
6. Medicare eligibility on basis of disability or ESRD N = 31,216
7. Date of death differed by > 3 months between SEER and Medicare databases N = 31,216
8. NSCLC diagnosis at death or autopsy N = 31,158
Diagnosed with Stage IIIB/IV 
(N =16,073)
Newly diagnosed NSCLC 
between 1997-2002 
(N = 31,158)
All Stage IIIB/IV patients treated with 
first-line chemotherapy 
(N =5,410)
Stage IIIB/IV patients treated with 
identifiable first-line chemotherapy 
(N =4,230)
Stage IIIB/IV patients treated with identifiable 
first-line doublet chemotherapy 
(N =3,130)
Figure 1 Flow of patients with stage IIIB/IV NSCLC who received ﬁrst-line chemotherapy from identiﬁcation to sample inclusion. ESRD, end-stage renal disease;
HMO, health maintenance organization; NSCLC, non–small-cell lung cancer; SEER, Surveillance, Epidemiology and End Results.
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distribution of the scores by treatment across strata was assessed.
For each treatment group, bootstrap samples were drawn (one-
ﬁfth of treatment total sample size drawn from each stratum), and
the mean cost differences between groups were computed. In the
bootstrapping process, 25,000 replications were produced, and
the percentile method was utilized to create conﬁdence intervals
(CI) on mean cost differences [14]. Because the KMSA estimator
suggested that censoring did not have a large impact on differential
cost estimates, adjusted results from only the propensity score bin
bootstrapping analyses are reported here.
All costs were inﬂated to 2005 US dollars by using the
medical-care services component of the Consumer Price Index.
Results
Patient Characteristics
A total of 31,158 patients newly received a diagnosis of NSCLC
between 1997 and 2002 met all initial study inclusion criteria
(Fig. 1). Approximately 34% (n = 10,475) received a diagnosis
of stage IV, and 18% (n = 5598) received a diagnosis of stage
IIIB. Of these, 5410 received ﬁrst-line chemotherapy, 4230 of
whom had records allowing for identiﬁcation of a speciﬁc che-
motherapy regimen, and 3130 of whom received a doublet
regimen. This last group comprised the ﬁnal analytic sample.
Regardless of type of doublet therapy received, the majority
of study patients receiving ﬁrst-line doublet therapy for advanced
NSCLC were between 65 and 74 years of age, male, white, and
living in a metropolitan area (Table 1). The median duration of
Medicare follow-up varied by type of doublet therapy ranging
from a maximum of 8.2 months among those receiving P + TAX
to a minumum of 6.4 months among those receiving OTHER
doublets.
Utilization of First-Line Doublet Therapy
Doublets containing P + TAX were the most frequently used
regimens across all study years. Use of taxane-containing dou-
Table 1 Baseline characteristics for older patients with stage IIIB/IV NSCLC treated with ﬁrst-line doublet chemotherapy, SEER–Medicare data
1997–2003
Characteristics
Doublet chemotherapy regimens
Cisplatin/carboplatin
and docetaxel/paclitaxel
(P + TAX)
Cisplatin/carboplatin
and gemcitabine
(P +GEM)
Cisplatin/carboplatin
and other
(P +OTHER)
Other doublet
therapies
(OTHER)*
Number of patients 2,271 373 307 179
Type of chemotherapy used, n (%):
Chemotherapy only 1,167 (51.4) 265 (71.0) 145 (47.2) 128 (71.5)
Chemotherapy, surgery 53 (2.3) 9 (2.4) 4 (1.3) 3 (1.7)
Chemotherapy, radiotherapy 999 (44.0) 98 (26.3) 153 (49.8) 46 (25.7)
Chemotherapy, surgery, radiotherapy 52 (2.3) 1 (0.3) 5 (1.6) 2 (1.1)
Age as of initial NSCLC diagnosis:
Mean (SD) 73 (4.7) 73 (4.8) 73 (4.8) 74 (4.8)
Median 73 73 72 73
Interquartile range 69–76 70–77 69–76 70–78
Age as of initial NSCLC diagnosis, n (%)
65–74 years 1,483 (65.3) 220 (59.0) 204 (66.4) 104 (58.1)
75–84 years 755 (33.2) 149 (39.9) 97 (31.6) 74 (41.3)
85+ years 33 (1.5) 4 (1.1) 6 (2.0) 1 (0.6)
Male, n (%) 1,362 (60.0) 205 (55.0) 187 (60.9) 102 (57.0)
Race, n (%)
White, Non-Hispanic 2,062 (90.8) 340 (91.2) 260 (84.7) 153 (85.5)
Black, Non-Hispanic 122 (5.4) 16 (4.3) 24 (7.8) 15 (8.4)
Hispanic 15 (0.7) 3 (0.8) 4 (1.3) 4 (2.2)
Asian 39 (1.7) 9 (2.4) 12 (3.9) 2 (1.1)
Other 33 (1.5) 5 (1.3) 7 (2.3) 5 (2.8)
Geographic region, n (%)
Midwest 423 (18.6) 91 (24.4) 108 (35.2) 23 (12.8)
Northeast 488 (21.5) 62 (16.6) 40 (13.0) 41 (22.9)
South 507 (22.3) 74 (19.8) 36 (11.7) 57 (31.8)
West 853 (37.6) 146 (39.1) 123 (40.1) 58 (32.4)
Location of residence, n (%)
Metropolitan 1,936 (85.2) 318 (85.3) 259 (84.4) 149 (83.2)
Urban 300 (13.2) 51 (13.7) 46 (15.0) 28 (15.6)
Rural 35 (1.5) 4 (1.1) 2 (0.7) 2 (1.1)
Household income by zip code ($)
Mean (SD) 36,434 (14,752) 36,762 (14,752) 35,872 (15,167) 36,905 (15,648)
Median 34,449 34,868 33,872 35,815
Interquartile range 25,817–43,319 26,396–43,616 25,115–41,722 23,116–47,998
Charlson comorbidity index†
Mean (SD) 0.17 (0.5) 0.21 (0.6) 0.18 (0.5) 0.25 (0.8)
Median 0 0 0 0
Interquartile range 0–0 0–0 0–0 0–0
Length of Medicare follow-up (months):
Mean (SD) 11.7 (11.3) 10.9 (9.0) 12.3 (13.0) 9.3 (9.0)
Median 8.2 8.1 7.6 6.5
Interquartile range 4.2–14.8 4.4–14.6 4.1–15.8 3.4–12.2
*Nonplatinum OTHER doublet therapies included taxane + gemcitabine, taxane + vinorelbine, taxane + irinotecan, taxane + vinblastine, gemcitabine + vinorelbine, gemcitabine + irinotecan,
vinorelbine +mitomycin, etoposide +mitomycin, vinblastine +mitomycin, irinotecan +mitomycin.
†Charlson comorbidity index excluding chronic obstructive pulmonary disease and cancer.
SEER, Surveillance, Epidemiology and End Results; P, cisplatin/carboplatin; GEM, gemcitabine;TAX, taxane (refers to docetaxel or paclitaxel).
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blets increased from 51.1% in 1997 to 54.5% among study
patients treated with identiﬁable chemotherapy in 2002. Sub-
stantial increases in the use of gemcitabine as ﬁrst-line chemo-
therapy were also seen in patients over the study period. Use of
P + GEM increased from 0.3% among those who received a
diagnosis in 1997 to 11.8% among those who received a diag-
nosis in 2002. Use of P + OTHER decreased markedly from
18.9% among those who received a diagnosis in 1997 to 3.7%
among those who receiveda diagnosis in 2002, while the use of
OTHER doublets increased over time.
Lifetime and On-Treatment Medical-Care Costs
Unadjusted lifetime medical-care costs among study patients
totaled approximately $70,000, with almost half incurred while
on ﬁrst-line treatment. These costs ranged from approximately
$66,000 among patients treated with OTHER doublets to almost
$74,000 among patients treated with P + OTHER. Mean lifetime
medical costs were $72,183 among patients treated with
P + TAX and $67,193 among patients treated with P + GEM.
Unadjusted total lifetime medical-care costs per month ranged
from $6004 to $7146 for all treatment groups. Lifetime medical
costs were dominated by hospitalization and physician costs,
which represented more than 85% of total costs.
Unadjusted total costs while on doublet therapy ranged from
$28,562 among patients treated with P + GEM to $34,516
among those treated with P + TAX (Table 2). Costs were again
dominated by hospitalization and physician costs, which repre-
sented 80% to 86% of total costs. Monthly on-treatment costs
ranged from $10,311 among patients treated with P + GEM to
$12,784 among those treated with P + TAX.
Estimates from bootstrapping models indicated that among
patients treated with ﬁrst-line P + TAX, lifetime medical-care
costs were signiﬁcantly higher than those for patients treated
with P + GEM, with a mean difference of $4781 (95%
CI = $1558–$8039) (Table 3) between treatments. Costs for each
component of total lifetime medical-care costs were lower among
patients who received P + GEM, with the largest differences seen
in hospital, outpatient, and physician costs.
Additionally, patients treated with OTHER doublet therapy
had signiﬁcantly lower total lifetime medical costs than patients
who received P + TAX, with a difference of $5961 (95%
CI = $2333–$9614) between treatments. This difference was
mainly a result of differences in hospital and outpatient costs.
Adjusted total on-treatment costs among patients treated
with ﬁrst-line P + TAX were signiﬁcantly higher than those for
several other doublet therapies (Table 3). Patients treated with
P + GEM had signiﬁcantly lower total on-treatment costs than
those who received P + TAX with a difference of $5825 (95%
CI = $3872–$7770) between treatments. Patients treated with
P + GEM had lower costs for each component of total
on-treatment costs than those who received P + TAX. The largest
Table 2 Unadjusted total on-treatment medical-care costs for patients at stage IIIB/IV with NSCLC, by ﬁrst-line doublet chemotherapy, SEER–Medicare
data 1997–2003
Characteristics
Doublet chemotherapy regimens
Cisplatin/carboplatin
and docetaxel/paclitaxel
(P + TAX)
Cisplatin/carboplatin
and gemcitabine
(P +GEM)
Cisplatin/carboplatin
and other
(P +OTHER)
Other doublet
therapies
(OTHER)*
Number of patients 2,271 373 307 179
Length of time on doublet regimen (months)
Mean (SD) 2.70 (2.18) 2.77 (2.12) 2.37 (2.39) 2.67 (2.07)
Median 2.27 2.33 1.90 2.10
Interquartile range 1.37–3.53 1.40–3.60 1.07–2.93 1.00–3.70
Hospital ($)
Mean (SD) 10,184 (17,699) 8,252 (12,602) 10,355 (15,002) 9,338 (13,318)
Median 5,902 4,145 6,281 6,385
Interquartile range 0–13,551 0–10,595 0–13,402 0–12,207
SNF ($)
Mean (SD) 1,045 (4,550) 743 (3,596) 949 (3,890) 687 (3,086)
Median 0 0 0 0
Interquartile range 0–0 0–0 0–0 0–0
Outpatient ($)
Mean (SD) 3,159 (5,154) 2,140 (3,232) 3,313 (4,530) 2,095 (3,281)
Median 1,382 925 1,580 879
Interquartile range 321–4,059 155–2,520 128–4,918 114–2,315
Physician ($)
Mean (SD) 18,013 (12,827) 16,035 (13,005) 12,874 (10,859) 17,499 (14,395)
Median 15,122 13,346 10,276 12,706
Interquartile range 9,483–23,671 7,449–21,180 6,381–16,342 6,817-24,119
Home health ($)
Mean (SD) 636 (1,769) 406 (1,138) 678 (2,298) 478 (1,425)
Median 0 0 0 0
Interquartile range 0-127 0-0 0-117 0-0
Hospice ($)
Mean (SD) 1,480 (5,418) 987 (3,268) 815 (2,625) 1,269 (3,125)
Median 0 0 0 0
Interquartile range 0-373 0-0 0-0 0-449
Total medical-care cost ($)
Mean (SD) 34,516 (28,350) 28,562 (22,819) 28,983 (24,346) 31,366 (24,012)
Median 27,567 22,853 21,258 25,318
Interquartile range 17,170-42,659 12,410-35,653 13,006-38,028 14,066-46,661
Total medical-care cost/month ($) 12,784 10,311 12,229 11,748
*OTHER doublet therapies included: taxane + gemcitabine, taxane + vinorelbine, taxane + irinotecan, taxane + vinblastine, gemcitabine + vinorelbine, gemcitabine + irinotecan,
vinorelbine +mitomycin, etoposide +mitomycin, vinblastine +mitomycin, irinotecan +mitomycin.
SEER, Surveillance, Epidemiology and End Results; P, cisplatin/carboplatin; GEM, gemcitabine; SNF, skilled nursing facility;TAX, taxane (refers to docetaxel or paclitaxel).
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differences between groups were seen in costs for hospitaliza-
tions, outpatient services, and physician services (Table 2).
Patients treated with P + OTHER also had signiﬁcantly lower
total on-treatment costs than those who received P + TAX with a
difference of $5968 (95% CI = $3995–$7975) (Table 3) between
treatments. Patients treated with P + OTHER actually had
slightly higher hospital and home health costs than those patients
who received P + TAX. Nevertheless, these patients had cost
offsets largely because of differences in physician services, which
contributed to the lower total on-treatment costs compared with
P + TAX (Table 2).
Patients treated with OTHER doublet therapy also had sig-
niﬁcantly lower total on-treatment costs than those who received
P + TAX with a difference of $3663 (95% CI = $1620–$5740)
(Table 3) between treatments. While patients treated with
OTHER doublet therapy had lower costs on all components of
total on-treatment costs, differences between OTHER doublet
and P + TAX were mainly a result of lower costs for hospitaliza-
tion and outpatient services (Table 2).
Supportive Medication Use and Adverse Events
Supportive medications associated with ﬁrst-line doublet chemo-
therapy were used by 40% to 49% of study patients (Table 4).
Megesterol acetate and ﬁlgrastim were the most commonly used
supportive medications regardless of doublet type.
Costs of supportive medications were a small component of
on-treatment costs and ranged from $533 among patients treated
with P + GEM to $693 among patients treated with OTHER
doublets (Table 4). Supportive medication costs per month
ranged from $192 among those treated with P + GEM to $280
among patients treated with P + OTHER.
Between 34% and 46% of study patients were hospitalized
for an adverse event (Table 4). Rates of adverse events causing
hospitalization were lower among patients treated with P + GEM
than those who received P + TAX (34.0% vs. 39.9%), which
likely contributed to the lower total on-treatment costs among
those who received P + GEM. Anemia, dehydration, infection,
and neutropenia were the most common adverse events leading
to hospitalization among patients who received ﬁrst-line doublet
chemotherapy. Patients treated with P + TAX reported slightly
higher rates of infection, neutropenia, dehydration, fever,
delirium, and mucositis than those who received P + GEM, while
those who received P + GEM reported slightly higher rates of
anemia, thrombocytopenia, and adverse events of systemic
therapy than those who received P + TAX.
Costs of hospitalizations for adverse events related to ﬁrst-
line doublet chemotherapy ranged from $3746 among patients
treated with P + GEM to $5149 among patients treated with
P + OTHER (Table 4). Monthly costs of hospitalizations for
adverse events related to ﬁrst-line doublet chemotherapy ranged
from $1352 per month among those treated with P + GEM to
$2173 among patients treated with P + OTHER.
Discussion
This retrospective analysis evaluated total lifetime medical-care
costs and costs associated with ﬁrst-line doublet chemotherapy
use in older patients with stage IIIB/IV NSCLC who received a
diagnosis between 1997 and 2002 using linked SEER–Medicare
data. The study indicates that among ﬁrst-line chemotherapy
regimens, there is a cost differential between doublet therapies in
terms of lifetime medical-care costs and on-treatment costs for
these patients. Total lifetime costs and costs during ﬁrst-line
doublet therapy were substantially dominated by hospitalization
and physician costs. Although doublet therapy with P + TAXwas
the most frequently utilized regimen, it had the highest lifetime
costs and costs while on treatment.
Patients treated with P + GEM had the lowest mean total
lifetime costs and on-treatment costs. All components of total
lifetime and on-treatment costs were lower among patients
treated with P + GEM than those of patients who received
P + TAX, with the greatest differences between treatment groups
seen in hospital, outpatient, and physician services.
While utilization of supportive medications was frequent in
study patients, costs associated with these treatments were a
Table 3 Pairwise comparisons of total lifetime and on-treatment
medical-care costs for stage IIIB/IV NSCLC patients by ﬁrst-line doublet
chemotherapy: observed and adjusted using propensity score bin boot-
strapping (2005 US$), SEER–Medicare data 1997–2003
Comparators/measures
Difference in
costs ($)*
95% conﬁdence
interval ($)
Total lifetime medical-care costs
Platinum and taxane vs. platinum
and gemcitabine
Observed difference (mean) 4,989 429–9,550
Adjusted difference (mean) 4,781 1,558–8,039
Platinum and other vs. platinum
and gemcitabine
Observed difference (mean) 6,523 -331 to 13,377
Adjusted difference (mean) 3,404 -3,143 to 9,973
Other doublet† vs. platinum and
gemcitabine
Observed difference (mean) -850 -8,764 to 7,065
Adjusted difference (mean) -1,685 -8,856 to 5,484
Platinum and other vs. platinum
and taxane
Observed difference (mean) 1,534 -4,218 to 7,285
Adjusted difference (mean) 219 -3,336 to 3,777
Other doublet† vs. platinum and
taxane
Observed difference (mean) -5,839 -12,820 to 1,142
Adjusted difference (mean) -5,961 -9,614 to -2,333
Other doublet† vs. platinum and
other
Observed difference (mean) -7,373 -16,029 to 1,283
Adjusted difference (mean) -5,384 -13,845 to 3,101
Total on-treatment medical-care costs
Platinum and taxane vs. platinum
and gemcitabine
Observed difference (mean) 5,954 3,361–8,548
Adjusted difference (mean) 5,825 3,872–7,770
Platinum and other vs. platinum
and gemcitabine
Observed difference (mean) 421 -3,155 to 3,997
Adjusted difference (mean) 64 -3,368 to 3,481
Other doublet† vs. platinum and
gemcitabine
Observed difference (mean) 2,804 -1,408 to 7,016
Adjusted difference (mean) 2,572 -1,386 to 6,471
Platinum and other vs. platinum
and taxane
Observed difference (mean) -5,534 -8,497 to -2,570
Adjusted difference (mean) -5,968 -7,975 to -3,995
Other doublet† vs. platinum and
taxane
Observed difference (mean) -3,150 -6,857 to 556
Adjusted difference (mean) -3,663 -5,740 to -1,620
Other doublet† vs. platinum and
other
Observed difference (mean) 2,383 -2,066 to 6,833
Adjusted difference (mean) 3,023 -1,205 to 7,223
*All differences are calculated as therapy 1 to therapy 2.
†OTHER doublet therapies included taxane + gemcitabine, taxane + vinorelbine,
taxane + irinotecan, taxane + vinblastine, gemcitabine + vinorelbine, gemcitabine + irino-
tecan, vinorelbine +mitomycin, etoposide +mitomycin, vinblastine +mitomycin, irinotecan +
mitomycin.
Platinum refers to cisplatin or carboplatin; taxane refers to docetaxel or paclitaxel.
NSCLC, non–small-cell lung cancer; SEER, Surveillance, Epidemiology and End Results.
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small component of on-treatment medical costs. Costs of sup-
portive medications were lowest among patients who received
P + GEM than those of other doublet regimens. Adverse events
requiring hospitalization were seen in less than half of patients
treated with ﬁrst-line doublet chemotherapy. Total and monthly
costs of hospitalization for adverse events were lowest among
patients who received P + GEM.
Unit cost data for chemotherapy regimens were not available
on outpatient claims, precluding analyses examining the effect of
ﬁrst-line chemotherapy drug costs on total lifetime medical-care
costs. Hospital days accounted for 70% of total costs. Neverthe-
less, details on the speciﬁc costs incurred while on ﬁrst-line
chemotherapy were not reported.
Ramsey et al. evaluated mean lifetime costs for older persons
with stage IIIB/IVNSCLCwho received a diagnosis between 1994
and 1999 and found costs were higher for those who received
ﬁrst-line chemotherapy than for those who did not. Mean lifetime
medical-care costs were $78,451 among those receiving doublet
therapy with P + TAX and $68,173 among those receiving P plus
an agent other than a taxane [8]. The ﬁndings of the current study
are consistent with those from Ramsey et al., with both studies
reporting the highest lifetimemedical costs among patients receiv-
ing regimens containing a platinum plus a taxane compared with
those receiving other chemotherapy regimens.
The current study explores more recent data and adds to the
existing medical literature by focusing on total lifetime and
on-treatment costs incurred by older patients with advanced
NSCLC who received doublet ﬁrst-line regimens, which are com-
monly used in clinical practice. This study explores more recent
SEER–Medicare data (initial NSCLC diagnoses from 1997 to
2002), which allows for fuller examination of the utilization and
costs associated with taxanes and newer agents, including gem-
citabine. Additionally, the present study provides estimates of
costs for supportivemedications and hospitalizations from serious
adverse events associated with ﬁrst-line doublet chemotherapy.
Previous studies evaluating lifetime or on-treatment costs in
NSCLC have not provided this level of detail.
While this study contributes important information on life-
time and on-treatment costs associated with ﬁrst-line doublet
chemotherapy use in older patients with advanced NSCLC, it is
subject to certain limitations. Retrospective analyses of Medicare
claims data are associated with standard limitations including
potential diagnostic and procedural coding inaccuracies, incom-
plete data, and lack of generalizability to non-Medicare beneﬁ-
ciaries. Nevertheless, SEER–Medicare data have been used in
several published studies in a variety of cancers, including
cancers of the breast, prostate, lung, and colon, among others
[10,16,17].
SEER data from 1997 to 2002 and Medicare data through
2003 were utilized; thus, costs from 2004 to the present cannot
be determined. Nevertheless, when data become available,
further studies to evaluate use of newer targeted agents or revised
Table 4 Frequency and cost of palliative/supportive care and hospitalizations due to adverse events in stage IIIB/IV NSCLC patients, by ﬁrst-line doublet
chemotherapy, SEER–Medicare data 1997–2003
Characteristic
Doublet chemotherapy regimens
Cisplatin/carboplatin
and docetaxel/paclitaxel
(P + TAX)
Cisplatin/carboplatin
and gemcitabine
(P +GEM)
Cisplatin/carboplatin
and other
(P +OTHER)
Other doublet
therapies
(OTHER)*
Number of patients 2271 373 307 179
Length of time on doublet regimen (Days)
Mean (SD) 80.9 (65.4) 83.1 (63.5) 71.3 (71.7) 80.8 (62.6)
Median 68 70 57 64
Interquartile range 41–106 42–108 32–88 31–111
Palliative/supportive treatments, n (%)†
Any palliative/supportive treatment 927 (40.8) 183 (49.1) 120 (39.1) 88 (49.2)
Megesterol acetate 571 (25.1) 127 (34.0) 68 (22.1) 52 (29.1)
Filgrastim (G-CSF) 404 (17.8) 72 (19.3) 71 (23.1) 33 (18.4)
Fentanyl 62 (2.7) 12 (3.2) 9 (2.9) 14 (7.8)
Sargramostim (GM-CSF) 74 (3.3) 11 (2.9) 16 (5.2) 4 (2.2)
Erythropoietin 57 (2.5) 12 (3.2) 4 (1.3) 8 (4.5)
Antiemetic 58 (2.6) 14 (3.8) 5 (1.6) 5 (2.8)
Adverse events, n (%)†
Any adverse event causing hospitalization 907 (39.9) 127 (34.0) 121 (39.4) 82 (45.8)
Anemia 423 (18.6) 75 (20.1) 63 (20.5) 43 (24.0)
Dehydration 427 (18.8) 45 (12.1) 55 (17.9) 40 (22.3)
Infection 291 (12.8) 37 (9.9) 48 (15.6) 26 (14.5)
Neutropenia 139 (6.1) 20 (5.4) 33 (10.7) 15 (8.4)
Delirium 186 (8.2) 23 (6.2) 26 (8.5) 14 (7.8)
Mucositis 84 (3.7) 6 (1.6) 12 (3.9) 3 (1.7)
Fever 46 (2.0) 3 (0.8) 5 (1.6) 6 (3.4)
Thrombocytopenia 20 (0.9) 8 (2.1) 4 (1.3) 4 (2.2)
Supportive medication costs ($)
Mean (SD) 612 (2075) 533 (1885) 664 (2205) 693 (2012)
Median 0 0 0 0
Interquartile range 0-87 0-149 0-324 0-277
Supportive medication costs/month ($) 227 192 280 260
Costs of hospitalization due to AEs ($)
Mean (SD) 4814 (8528) 3746 (6182) 5149 (8602) 4446 (8511)
Median 0 0 0 0
Interquartile range 0-7721 0-6951 0-7990 0-7426
AE Hospitalization costs per month ($) 1783 1352 2173 1665
*OTHER doublet therapies included: taxane + gemcitabine, taxane + vinorelbine, taxane + irinotecan, taxane + vinblastine, gemcitabine + vinorelbine, gemcitabine + irinotecan,
vinorelbine +mitomycin, etoposide +mitomycin, vinblastine +mitomycin, irinotecan +mitomycin.
†Includes only those events reported in more than 2 percent of any treatment arm.
NSCLC, non–small-cell lung cancer; SEER, Surveillance, Epidemiology and End Results; AE, adverse events; G-CSF, granulocyte colony-stimulating factor; GEM, gemcitabine; GM-CSF,
granulocyte/macrophage colony-stimulating factor; P, cisplatin/carboplatin;TAX, taxane (refers to docetaxel or paclitaxel).
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indications for existing cytotoxics are warranted [18–20]. Only
those services covered by Medicare are included in this analysis,
and, at the time of this study, coverage for oral prescription
medications was not included. Examination of the differences in
on-treatment costs for second- and third-line chemotherapy may
inﬂuence total lifetime medical-care costs. Thus, to fully evaluate
the utilization of chemotherapy including second- and third-line
options, a data source containing both intravenous and oral
chemotherapy agents will be needed for future analyses. Addi-
tionally, the study sample includes only those individuals who
have health coverage via Medicare. While this age group repre-
sents the majority of patients with NSCLC, this sample is not
representative of all US patients, particularly those with other
forms of health insurance (e.g., managed care, private pay).
Unit cost data for chemotherapy regimens do not exist on
outpatient visit claims, and costs of speciﬁc medications cannot
be identiﬁed. This precluded analyses examining the effect of
ﬁrst-line chemotherapy drug costs on total lifetime medical-care
costs. Additionally, certain clinical outcomes, including treat-
ment discontinuation and length of time on treatment, could not
be directly observed by using the SEER–Medicare data; thus,
algorithms developed with clinical experts were relied on, result-
ing in rates of treatment discontinuation and estimates of
length of time on treatment matching those observed in clinical
practice.
Because nonrandomized groups were compared, differences
in costs between groups may be a result of factors other than the
treatment regimens if all confounders are not accounted for in
the analyses. The analyses controlled for a set of covariates using
a propensity score approach, and both unadjusted and adjusted
analyses were presented. Nevertheless, adjustment factors were
limited to data available in the database and one cannot rule out
potential differences in other factors. Such propensity score
adjustment does not control for potential biases from unmea-
sured variables that are not highly correlated with factors
included in the model. Of particular note was addressing differ-
ences in follow-up care, including both follow-up duration and
second-line treatment. The KMSA analysis suggested that cen-
soring had a minimal impact on treatment differences in total
costs. Nevertheless, computation of costs per month (averaged
over lifetime) rather than total lifetime costs showed similar
values for P + TAX and P + GEM. Costs per month averaged
over time on treatment were in agreement with the total
costs while on treatment (lower costs for P + GEM). Thus,
further research on the issue of duration and follow-up costs is
warranted.
Source of ﬁnancial support: This study was funded by Eli Lilly and
Company.
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